Elizabeth H.Z. Thompson is the Executive Vice President and Head of Research and Development at ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative medicines to address unmet medical needs in central nervous system disorders. With over two decades of experience in the biopharmaceutical industry, Thompson has a strong background in drug development, particularly in neuroscience and oncology. She holds a Ph.D. in Pharmacology from the University of California, San Diego, and has held various leadership positions at several prominent companies, including Pfizer and Medivation. At ACADIA Pharmaceuticals, Thompson leads the company's research and development efforts, overseeing a portfolio of clinical-stage programs aimed at treating a range of neurological and psychiatric conditions. Her strategic vision and scientific expertise have been instrumental in advancing ACADIA's pipeline, which includes promising therapies for Parkinson's disease psychosis, Alzheimer's disease psychosis, and other central nervous system disorders. Under her leadership, the company has successfully navigated the complex landscape of drug development, bringing innovative treatments closer to patients in need. Thompson's contributions to the field extend beyond her role at ACADIA. She is an active member of several professional organizations, including the American Society for Pharmacology and Experimental Therapeutics, and has authored numerous publications in peer-reviewed journals. Her dedication to advancing scientific knowledge and improving patient outcomes has earned her recognition as a thought leader in the biopharmaceutical industry. As ACADIA continues to grow and expand its research efforts, Thompson's leadership will be crucial in driving the company's mission to transform the lives of patients with central nervous system disorders.